Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Sales (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Return on Sales data on record, last reported at 2.45% in Q4 2025.

  • For Q4 2025, Return on Sales rose 358.0% year-over-year to 2.45%; the TTM value through Dec 2025 reached 0.87%, up 109.0%, while the annual FY2025 figure was 4.35%, 240.0% down from the prior year.
  • Return on Sales reached 2.45% in Q4 2025 per LCTX's latest filing, up from 0.93% in the prior quarter.
  • Across five years, Return on Sales topped out at 2.45% in Q4 2025 and bottomed at 13.83% in Q2 2021.
  • Average Return on Sales over 5 years is 3.38%, with a median of 2.31% recorded in 2023.
  • Peak YoY movement for Return on Sales: surged 1269bps in 2021, then crashed -372bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 3.9% in 2021, then plummeted by -64bps to 6.39% in 2022, then soared by 64bps to 2.31% in 2023, then skyrocketed by 51bps to 1.13% in 2024, then soared by 316bps to 2.45% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 2.45% in Q4 2025, 0.93% in Q3 2025, and 6.99% in Q2 2025.